<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koh, Kwang Kon</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Multiple Targeted Therapy is Critical for Reducing Cardiometabolic Risk</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">16-17</style></pages><abstract><style  face="normal" font="default" size="100%">Obesity is associated with a range of adverse metabolic consequences, including endothelial dysfunction, systemic inflammation, and insulin resistance. Therefore, to provide effective protection against the development of atherosclerosis and heart disease, obese patients require combination drug regimens that target several cardiometabolic risk factors.</style></abstract><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>